A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer - Wikidata - wikimedia - TriplyDB

A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer

A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer

http://www.wikidata.org/entity/Q34650878

about

Photo-activated psoralen binds the ErbB2 catalytic kinase domain, blocking ErbB2 signaling and triggering tumor cell apoptosis ESR1 is co-expressed with closely adjacent uncharacterised genes spanning a breast cancer susceptibility locus at 6q25.1 Mechanisms of resistance and sensitivity to anti-HER2 therapies in HER2+ breast cancer What a tangled web we weave: emerging resistance mechanisms to inhibition of the phosphoinositide 3-kinase pathway Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer Mechanisms and therapeutic advances in the management of endocrine-resistant breast cancer Human epidermal growth factor receptor family-targeted therapies in the treatment of HER2-overexpressing breast cancer Lapatinib Plasma and Tumor Concentrations and Effects on HER Receptor Phosphorylation in Tumor Resistance to therapy in estrogen receptor positive and human epidermal growth factor 2 positive breast cancers: progress with latest therapeutic strategies From bench to bedside: What do we know about hormone receptor-positive and human epidermal growth factor receptor 2-positive breast cancer?PP2A: The Wolf in Sheep's Clothing?Proteomic analyses reveal distinct chromatin-associated and soluble transcription factor complexes Differences in the binding affinities of ErbB family: heterogeneity in the prediction of resistance mutants Modulation of ErbB2 blockade in ErbB2-positive cancers: the role of ErbB2 Mutations and PHLDA1 Bazedoxifene exhibits antiestrogenic activity in animal models of tamoxifen-resistant breast cancer: implications for treatment of advanced disease.Dual HER2 blockade: preclinical and clinical data Monoclonal antibody against the ectodomain of E-cadherin (DECMA-1) suppresses breast carcinogenesis: involvement of the HER/PI3K/Akt/mTOR and IAP pathways ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics.Personalizing HER2-targeted therapy in metastatic breast cancer beyond HER2 status: what we have learned from clinical specimens Niche-localized tumor cells are protected from HER2-targeted therapy via upregulation of an anti-apoptotic program in vivo.EGFR/HER2 inhibitor AEE788 increases ER-mediated transcription in HER2/ER-positive breast cancer cells but functions synergistically with endocrine therapy.Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapy ERRF sensitizes ERBB2-positive breast cancer cells to lapatinib treatment likely by attenuating MCL1 and ERBB2 expression A phase I-II study of combined blockade of the ErbB receptor network with trastuzumab and gefitinib in patients with HER2 (ErbB2)-overexpressing metastatic breast cancer.Dynamic modelling of oestrogen signalling and cell fate in breast cancer cells Quantitative optical imaging of primary tumor organoid metabolism predicts drug response in breast cancer.X-linked inhibitor of apoptosis protein inhibits apoptosis in inflammatory breast cancer cells with acquired resistance to an ErbB1/2 tyrosine kinase inhibitor.Targeting HER2 in breast cancer: overview of long-term experience The molecular mechanisms underlying the pharmacological actions of ER modulators: implications for new drug discovery in breast cancer.Targeted treatment of advanced and metastaticbreast cancer with lapatinib.Modeling the estrogen receptor to growth factor receptor signaling switch in human breast cancer cells PP2A inhibition overcomes acquired resistance to HER2 targeted therapy.Therapeutic strategies and mechanisms of tumorigenesis of HER2-overexpressing breast cancer FOXA1 as a therapeutic target for breast cancer.BikDD eliminates breast cancer initiating cells and synergizes with lapatinib for breast cancer treatment Mitochondrial MKP1 is a target for therapy-resistant HER2-positive breast cancer cells.Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase.The turnover of estrogen receptor α by the selective estrogen receptor degrader (SERD) fulvestrant is a saturable process that is not required for antagonist efficacy Pathologic complete response after preoperative anti-HER2 therapy correlates with alterations in PTEN, FOXO, phosphorylated Stat5, and autophagy protein signaling.Simultaneous Inhibition of Estrogen Receptor and the HER2 Pathway in Breast Cancer: Effects of HER2 Abundance

P2860

Q21132316-392770AC-1D96-4B50-B508-6B75DD66B3E6 Q21563388-AD1963FE-5F0D-4AF3-AA95-5636EA23669B Q26772969-053BD45D-8EC5-4AD2-966C-86F283AF071B Q26825780-10222CC7-EB11-48F1-AD27-806D5E2ACF7E Q26862550-9C9AD24A-416F-4395-A307-F34CAB12929A Q27001260-63C2974E-2AF5-4C77-B61D-D6C3856E7EE9 Q27025863-DCA41A02-D546-4B5F-8AC2-70066673627B Q27342948-DAB03470-90A9-4A67-9F79-503CC1A8D97A Q28072897-B1B805A3-78B4-44C9-98EF-4896782C3057 Q28084982-78FCE840-0CEB-4847-992E-468C24BCA7B4 Q28088747-DC406369-39A8-4DBB-9186-EDEC1F09894F Q28115646-CF5484BB-2049-4518-B330-9E67AB5A1032 Q28534601-6EFF3814-156D-40D4-BE02-8BBE54A6D9E2 Q28655621-E96C5D2E-274E-4BC3-8890-3694C0DD4E7F Q30413295-5FA209E7-4F32-43BB-AA91-173D44B90754 Q30941327-695803F1-616F-4BDD-88CE-072FC41AC795 Q33584432-11D6614F-9B22-419F-9D3B-D836FDD0563D Q33601653-0888961B-BA2B-4F6C-9A5D-47011FCE4E95 Q33735413-1B82DB84-CA03-41BF-BBDD-4D77611B67B9 Q33767497-F0818CC6-D257-4081-9DA6-E58C53F5C360 Q33794923-0A990920-1F1F-448F-8B98-636615F7855C Q33828409-FC4EDEE6-976B-47F3-8C7B-E86B32564C4E Q33829405-0AC55F3D-F02B-4CC9-A26C-3E073753BA7A Q34077853-0B814670-0D24-4085-88FD-67A88448A9B5 Q34192940-8932219D-E96F-415B-9FC2-C56C4C73BBA8 Q34205196-B54D7937-2709-4FDA-9FBC-90A071BC98D1 Q34214918-D7F5B5CD-6E08-4A39-83E9-D6B76469D054 Q34272044-6858A599-F12C-4D0A-9690-089EF189A766 Q34311300-933E1A99-0CEB-4E3B-BA1C-30B982103C0A Q34363419-990CFE09-A78B-4B69-8656-C0C168C694D8 Q34367908-23FADDFF-939C-4C36-B4AE-D7F6882661B3 Q34504365-9103B3FB-B4F2-4D40-88C5-8417CFF05D05 Q34570753-69584760-4A28-471D-B492-8EDAA38291E7 Q34610510-34ED42E5-6304-4653-9877-7B436E4F7448 Q34632169-AC965508-E710-4EFB-A4BD-057780D11E1E Q34713726-580A05C5-ED7C-4E0A-93A7-5635A179C87B Q34720797-87D3A910-A0D5-4DDF-AD54-131258E325F3 Q35027844-6C548E8B-10CB-41C0-87E8-093B747B73C1 Q35058975-59BA3BC7-A037-4584-A9D3-9D7DAEA7B3A1 Q35182591-85D915FD-0479-409A-A2CB-4C9DBF5E7CC1

P2860

A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer

http://www.wikidata.org/entity/Q34650878

description

2006 nî lūn-bûn

@nan

2006 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

A model of acquired autoresist ...... ent its onset in breast cancer

@ast

A model of acquired autoresist ...... ent its onset in breast cancer

@en

A model of acquired autoresist ...... ent its onset in breast cancer

@nl

type

label

A model of acquired autoresist ...... ent its onset in breast cancer

@ast

A model of acquired autoresist ...... ent its onset in breast cancer

@en

A model of acquired autoresist ...... ent its onset in breast cancer

@nl

prefLabel

A model of acquired autoresist ...... ent its onset in breast cancer

@ast

A model of acquired autoresist ...... ent its onset in breast cancer

@en

A model of acquired autoresist ...... ent its onset in breast cancer

@nl

P1433

Q34650878-599E72A0-4224-4706-A524-36C81064D32B

P1476

Q34650878-9ED9DFA1-7A77-4712-A5F7-A87158F5E6A6

P2093

Q34650878-1F4BD165-B39F-4D5C-A015-3BCE5EB79D52

Q34650878-2FCAE706-013C-4E9E-B5A6-7BD7A5A3210D

Q34650878-393A46F8-5B63-44C3-98DA-DC2660860B1C

Q34650878-3D1AE9FB-8B90-44F8-8404-914304A042D6

Q34650878-46361FE7-1E2E-4DD2-A490-EFF44DFA1198

Q34650878-6D2BD49E-7AA8-4BD7-A3AA-24872E38CAC2

Q34650878-75DA7606-D71F-4280-8CF6-1965456E2EAA

Q34650878-98A65AE1-CA3F-4089-9231-07EE2441FED3

Q34650878-A32F7A6B-6B62-48A9-A82A-D72340FBF767

Q34650878-D1AEEE65-B2A8-444A-9E50-3DEC31CD9932

P2860

Q34650878-0E457C56-9813-453F-B3C0-3C78DD436B08

Q34650878-157D51A7-E52F-4EB3-88D3-BBC5E9FC7BFE

Q34650878-186B1110-5BBC-4792-B610-411D1E18C780

Q34650878-18968750-DFCA-4C18-966E-9EF2290D1956

Q34650878-1BE7D7D2-57BF-4039-898D-633FA93AEEBC

Q34650878-2ADAB48F-10CA-4573-917E-0662EF6AE584

Q34650878-2E512A37-BCDC-45A7-A87A-33D3E6863B17

Q34650878-32273D9F-B257-44CD-B10E-726CD9E3DBE5

Q34650878-3F818A01-62D0-428F-B440-E644D9BC43D4

Q34650878-40A64163-0C8D-4F9D-ABDD-9A4659A5013F

P304

Q34650878-B7635D36-E90D-4B2B-8F22-3F747F74FC3F

P31

Q34650878-A28BFA40-BFC0-4CD1-BEAB-0DB36872B82D

P356

Q34650878-D086AC3B-C0E1-4ACD-A976-4AA4A04EBCA3

P407

Q34650878-D30EF99D-375A-4DF9-9A54-5CC6B1B6AB76

P433

Q34650878-12317FA4-2C20-4F53-A3E6-5F3816C30D24

P478

Q34650878-55AF7B12-A200-4953-A9A0-3F81BE546AF3

P577

Q34650878-3AE0A965-EFB6-4139-AB76-789D002796B9

P5875

Q34650878-CDCAD445-48DB-42D0-9C89-1A7E5353F1C5

P698

Q34650878-D8780B89-744D-4B32-8E8B-E91476DC3E00

P932

Q34650878-ABA8D8FF-4811-4515-A9D3-3D83532B8C16

P356

PNAS.0602468103

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

A model of acquired autoresist ...... ent its onset in breast cancer

@en

P2093

Georgina Paulazzo

http://www.w3.org/2001/XMLSchema#string

Intisar Husain

http://www.w3.org/2001/XMLSchema#string

Jason Hill

http://www.w3.org/2001/XMLSchema#string

Jay Strum

http://www.w3.org/2001/XMLSchema#string

Jennifer Harris

http://www.w3.org/2001/XMLSchema#string

Leihua Liu

http://www.w3.org/2001/XMLSchema#string

Ljuba Lyass

http://www.w3.org/2001/XMLSchema#string

Neil L Spector

http://www.w3.org/2001/XMLSchema#string

Patricia Trusk

http://www.w3.org/2001/XMLSchema#string

Priti Hegde

http://www.w3.org/2001/XMLSchema#string

P2860

A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma

Ligand-independent activation of oestrogen receptor alpha by caveolin-1

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.

Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells.

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

The nuclear receptor superfamily: the second decade

Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas

Phosphatidylinositol 3-kinase signaling inhibits DAF-16 DNA binding and function via 14-3-3-dependent and 14-3-3-independent pathways

Ligand-independent activation of oestrogen receptor α by caveolin-1

Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials

P304

7795-7800

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.0602468103

http://www.w3.org/2001/XMLSchema#string

P407

P433

20

http://www.w3.org/2001/XMLSchema#string

P478

103

http://www.w3.org/2001/XMLSchema#string

P577

2006-05-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7097827

http://www.w3.org/2001/XMLSchema#string

P698

16682622

http://www.w3.org/2001/XMLSchema#string

P932

1472524

http://www.w3.org/2001/XMLSchema#string